• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    SC 13G/A 1 tv0728-dexcominc.htm SCHEDULE 13G/A dexcominc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 11)*

    Name of issuer:  Dexcom Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  252131107

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  252131107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    577,303

    7.  SOLE DISPOSITIVE POWER

    42,194,307

    8.  SHARED DISPOSITIVE POWER

    1,625,529

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    43,819,836

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.34%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Dexcom Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    6340 Sequence Drive
    San Diego, CA 92121

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    252131107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $DXCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    3/12/2024$165.00Outperform
    RBC Capital Mkts
    5/30/2023$131.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/13/24 5:02:33 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/23 11:16:37 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/22 3:43:37 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

      Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C

      4/10/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Dexcom Appoints Renée Galá to Board of Directors

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of patients and their families. In this role for Jazz Pharmaceuticals, Ms. Galá oversees global business operations including commer

      3/10/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Coleman Jon

      3 - DEXCOM INC (0001093557) (Issuer)

      3/31/25 6:57:22 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Director Heller Bridgette P sold $24,756 worth of shares (352 units at $70.33), decreasing direct ownership by 2% to 22,997 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      3/19/25 5:02:07 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Operating Officer Leach Jacob Steven sold $990,670 worth of shares (14,076 units at $70.38), decreasing direct ownership by 4% to 313,497 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      3/14/25 5:25:36 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Financials

    Live finance-specific insights

    See more
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start

      4/3/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-GAAP operating income* of $209.5 million or 18.8% of reported revenue, a decrease of 470 basis points compared to the fourth quar

      2/13/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by DexCom Inc.

      S-8 - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:18:23 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:10:04 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Dexcom with a new price target

      Mizuho initiated coverage of Dexcom with a rating of Outperform and set a new price target of $85.00

      4/10/25 12:40:59 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Dexcom from Neutral to Buy and set a new price target of $115.00 from $85.00 previously

      2/3/25 7:06:44 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Dexcom from Neutral to Outperform and set a new price target of $104.00 from $86.00 previously

      1/16/25 7:42:21 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care